Aethlon Medical, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended December 31, 2021; filed February 14, 2022. Aethlon is a clinical-stage medical technology company developing the Hemopurifier for cancer and life-threatening viral infections, and owns a majority interest in diagnostic subsidiary Exosome Sciences, Inc. (ESI).
Financial results
| Metric | Three months ended Dec. 31, 2021 | Three months ended Dec. 31, 2020 | Nine months ended Dec. 31, 2021 | Nine months ended Dec. 31, 2020 |
|---|---|---|---|---|
| Revenue, all government contracts | $17,117 | $624,871 | $281,049 | $624,871 |
| Operating expenses | $2.545 million | $3.069 million | $6.916 million | $6.252 million |
| Operating and net loss | $2.528 million | $2.444 million | $6.635 million | $5.627 million |
| Loss per share, basic and diluted | $0.16 | $0.20 | $0.46 | $0.50 |
| Operating cash used | Not presented quarterly | $6.668 million | $4.526 million |
- Revenue was grant and government-contract revenue, not commercial product sales. The quarter’s revenue came from a University of Pittsburgh subaward. Nine-month revenue included $229,698 from the NCI melanoma contract and $51,351 from the subaward.
- At December 31, cash was $20.395 million, restricted cash $87,506, working capital $20.141 million, total assets $21.916 million, and total liabilities $1.357 million. Liabilities included lease obligations; the filing reports no borrowings.
- Cash and restricted cash increased $10.574 million over the nine months, primarily because of $17.456 million in net equity proceeds, partly offset by operating and investing cash use. Property and equipment purchases were $137,000.
- Gross margin is not presented; the filing reports no cost-of-revenue line, so a meaningful product margin cannot be calculated from the provided statements.
Changes versus comparable periods
- Quarterly revenue fell $607,754 year over year, reflecting the absence of prior-year milestone revenue from the melanoma contract and the completed breast cancer grant. Quarterly operating expenses declined 17.1%, largely due to the prior-year former-CEO separation accrual and bonuses; net loss nevertheless rose about $84,000.
- Nine-month revenue declined $343,822, while operating expenses increased 10.6%. The resulting net loss increased about $1.008 million, or roughly 18%.
- Nine-month operating cash use increased $2.142 million. The company raised $4.948 million net through its at-the-market program and $11.659 million net in a registered direct offering, and received $821,000 from warrant exercises. These equity transactions increased shares outstanding.
Outlook, operations, and risks
- Management stated that December 31 cash was expected to fund operations for at least 12 months from the financial statements’ issuance. It also expects continued net losses and negative cash flows and anticipates significant spending on raw materials and an internal manufacturing facility. No revenue, profit, or clinical-trial guidance was provided.
- The Hemopurifier has FDA Breakthrough Device designations for specified cancer and viral-disease indications, but remains investigational. The head-and-neck cancer study had treated two patients and was recruiting. The U.S. COVID-19 study was designed for up to 40 patients at up to 20 centers; three hospitals were activated, and a site in India was open and screening patients.
- The company reported missing certain NCI melanoma-contract milestones for the September and December 2021 periods and deferred related invoices. It recognized previously deferred revenue after achieving earlier milestones. This creates uncertainty around timing of contract revenue.
- Key risks include clinical and regulatory failure or delay, the need for additional capital, manufacturing scale-up and compliance, competition, patent protection, reimbursement, and potential COVID-19 effects on trials and financing. Management said it could not assess the pandemic’s future effects. No pending or threatened legal proceedings were reported.
- New commitments include a five-year CRO agreement with PPD, cancellable by Aethlon on 30 days’ notice without cause, and leases for office, laboratory, and manufacturing space. The lab lease was expected to add approximately $400,797 in right-of-use assets and lease liabilities; the manufacturing lease was estimated to add approximately $614,240 upon occupancy.
- Subsequent events disclosed executive cash bonuses, 2022 salary and target-bonus changes, and executive option grants. Disclosure controls were assessed as effective, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Clinical-trial enrollment, site activation, safety and efficacy data, and progress toward regulatory approval.
- Achievement of remaining NCI contract milestones, deferred revenue recognition, and future grant funding.
- Cash runway against actual operating burn and planned manufacturing, clinical, and lease spending; management’s runway estimate is not a guarantee.
- Future capital needs and dilution risk following equity offerings, warrant exercises, and outstanding options and warrants.
- Manufacturing readiness, regulatory-compliant production capacity, and any impact of COVID-19 or other operational disruptions on trial timelines.